Mucosal immune regulation in murine amebic colitis

小鼠阿米巴结肠炎的粘膜免疫调节

基本信息

  • 批准号:
    7233217
  • 负责人:
  • 金额:
    $ 12.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-01 至 2008-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Amebic colitis is the most common form of amebiasis, a parasitic disease that accounts for 100,000 annual deaths. Human and experimental data have not clearly documented the nature of protective or deleterious acquired immunity in this infection. Recent work of ours using a C3H mouse model of amebic colitis has documented the capacity for acquired immunity to protect against colonization through vaccination as well as a deleterious role for CD4+ T cells in the development of disease. This research plan aims to focus on the latter, to define the mechanism of the CD4+ T cell response in disease pathogenesis. I hypothesize that dysregulated CD4+ T cells in amebic colitis contribute independently to both parasite burden and the development of intestinal inflammation. Possible mechanisms include IL-4 mediated phagocyte inhibition, mast cell induction, or loss of regulatory TGF-b production. Techniques will include in vivo blockade of key T helper cytokines by monoclonal antibody and depletion of phagocytes and mast cells. Development of the C3H SCID mouse model of infection will allow adoptive transfer experiments using CD4+ T cells and subsets therein to test the role of suppressor versus effector CD4+ T cells on the development of colitis. The work thus bridges the fields of parasite biology and mucosal immunology. Rigorous formal training in parasitology and immunology will occur during the first 2 years of the proposed research plan. The sponsor and cosponsor, investigators in molecular parasitology and mucosal immunology, respectively, will guide the laboratory component of the proposal. Additionally a supportive network of collaborators and consultants will be utilized from the departments of Immunology, Gastroenterology, Infectious Disease and Pathology throughout the University of Virginia and the United States Department of Agriculture. The comprehensive approach in training and research laid out in this research proposal will guide the applicant towards his goal of being an independent investigator in immunoparasitology.
描述(由申请人提供):阿米巴结肠炎是阿米巴病的最常见形式,阿米巴病是一种寄生虫病,每年造成10万人死亡。人类和实验数据还没有清楚地证明在这种感染中保护性或有害的获得性免疫的性质。我们最近使用阿米巴结肠炎的C3 H小鼠模型的工作已经证明了获得性免疫通过疫苗接种保护免受定植的能力以及CD 4 + T细胞在疾病发展中的有害作用。本研究计划旨在关注后者,以确定疾病发病机制中CD 4 + T细胞反应的机制。我推测阿米巴结肠炎中失调的CD 4 + T细胞独立地促进寄生虫负荷和肠道炎症的发展。可能的机制包括IL-4介导的吞噬细胞抑制、肥大细胞诱导或调节性TGF-β产生的丧失。技术将包括通过单克隆抗体在体内阻断关键的T辅助细胞因子以及吞噬细胞和肥大细胞的耗竭。C3 H SCID小鼠感染模型的开发将允许使用CD 4 + T细胞及其亚群的过继转移实验,以测试抑制性与效应性CD 4 + T细胞对结肠炎发展的作用。 因此,这项工作在寄生虫生物学和粘膜免疫学领域架起了桥梁。严格的正规培训,寄生虫学和免疫学将发生在头2年的拟议研究计划。申办者和共同申办者(分子寄生虫学和粘膜免疫学研究者)将分别指导提案的实验室部分。此外,还将利用弗吉尼亚大学和美国农业部免疫学、胃肠病学、传染病和病理学系的合作者和顾问的支持网络。本研究提案中提出的培训和研究综合方法将指导申请人实现成为免疫寄生虫学独立研究者的目标。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERIC R HOUPT其他文献

ERIC R HOUPT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERIC R HOUPT', 18)}}的其他基金

Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome
弗吉尼亚分枝杆菌肺病:复发和结果的测序和临床决定因素
  • 批准号:
    10543980
  • 财政年份:
    2021
  • 资助金额:
    $ 12.24万
  • 项目类别:
Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome
弗吉尼亚分枝杆菌肺病:复发和结果的测序和临床决定因素
  • 批准号:
    10321219
  • 财政年份:
    2021
  • 资助金额:
    $ 12.24万
  • 项目类别:
Diagnostics and Pharmacotherapy for Severe Forms of TB
严重结核病的诊断和药物治疗
  • 批准号:
    9127086
  • 财政年份:
    2015
  • 资助金额:
    $ 12.24万
  • 项目类别:
Diagnostics and Pharmacotherapy for Severe Forms of TB
严重结核病的诊断和药物治疗
  • 批准号:
    8819855
  • 财政年份:
    2015
  • 资助金额:
    $ 12.24万
  • 项目类别:
Genotyping and Pharmacokinetics in the HIV/MDR-TB epidemic of Eastern Siberia
东西伯利亚艾滋病毒/耐多药结核病流行的基因分型和药代动力学
  • 批准号:
    8793095
  • 财政年份:
    2014
  • 资助金额:
    $ 12.24万
  • 项目类别:
Genotyping and Pharmacokinetics in the HIV/MDR-TB epidemic of Eastern Siberia
东西伯利亚艾滋病毒/耐多药结核病流行的基因分型和药代动力学
  • 批准号:
    8605359
  • 财政年份:
    2014
  • 资助金额:
    $ 12.24万
  • 项目类别:
Reduced Injectable, Short-course for (E)Xpert MDR-TB [RISE trial]
(E)Xpert 耐多药结核病的短期注射减少 [RISE 试验]
  • 批准号:
    8732395
  • 财政年份:
    2014
  • 资助金额:
    $ 12.24万
  • 项目类别:
Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Disea
用于以患者为导向的传染病现场研究的分子诊断工具
  • 批准号:
    8580369
  • 财政年份:
    2013
  • 资助金额:
    $ 12.24万
  • 项目类别:
Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Diseases
用于以患者为导向的传染病现场研究的分子诊断工具
  • 批准号:
    10199920
  • 财政年份:
    2013
  • 资助金额:
    $ 12.24万
  • 项目类别:
Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Diseases
用于以患者为导向的传染病现场研究的分子诊断工具
  • 批准号:
    10443710
  • 财政年份:
    2013
  • 资助金额:
    $ 12.24万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 12.24万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 12.24万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 12.24万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 12.24万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 12.24万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 12.24万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 12.24万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 12.24万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 12.24万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 12.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了